This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: Diabetes treatment medication - XML Representation

Raw xml | Download

<Group xmlns="http://hl7.org/fhir">
  <id value="265092"/>
  <meta>
    <versionId value="5"/>
    <lastUpdated value="2025-03-15T21:02:00.141Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"/>
  </meta>
  <text>
    <status value="empty"/>
    <div xmlns="http://www.w3.org/1999/xhtml">[No data.]</div>
  </text>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name value="Sheyu Li"/>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as">
    <valueMarkdown
                   value="Diabetes treatment medication [Database Entry: FHIR Group Resource]. Contributors: Sheyu Li [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 265092. Revised 2024-11-16. Available at: https://fevir.net/resources/Group/265092. Computable resource at: https://fevir.net/resources/Group/265092#json."/>
  </extension>
  <url value="https://fevir.net/resources/Group/265092"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="urn:ietf:rfc:3986"/>
    <value value="https://fevir.net/FOI/265092"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <title value="Diabetes treatment medication"/>
  <status value="active"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <description
               value="SGLT-2 inhibitors, GLP-1 receptr agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, sulfonylureas, metformin, α-glucosidase inhibitors, meglitinides, insulins, dual GIP/GLP-1 receptor agonists, or non-steroidal mineralocorticoid receptor antagonists"/>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <membership value="conceptual"/>
  <combinationMethod value="any-of"/>
  <characteristic>
    <code>
      <text value="Drug class"/>
    </code>
    <valueCodeableConcept>
      <text value="SGLT-2 inhibitor"/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="SGLT-2 inhibitors"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Drug class"/>
    </code>
    <valueCodeableConcept>
      <text value="GLP-1 receptr agonist"/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="GLP-1 receptr agonists"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Drug class"/>
    </code>
    <valueCodeableConcept>
      <text value="DPP-4 inhibitor"/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="DPP-4 inhibitors"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Drug class"/>
    </code>
    <valueCodeableConcept>
      <text value="thiazolidinedione"/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="thiazolidinediones"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Drug class"/>
    </code>
    <valueCodeableConcept>
      <text value="sulfonylurea"/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="sulfonylureas"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Drug class"/>
    </code>
    <valueCodeableConcept>
      <text value="metformin"/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="metformin"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Drug class"/>
    </code>
    <valueCodeableConcept>
      <text value="α-glucosidase inhibitor"/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="α-glucosidase inhibitors"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Drug class"/>
    </code>
    <valueCodeableConcept>
      <text value="meglitinide"/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="meglitinides"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Drug class"/>
    </code>
    <valueCodeableConcept>
      <text value="insulin"/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="insulins"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Drug class"/>
    </code>
    <valueCodeableConcept>
      <text value="dual GIP/GLP-1 receptor agonist"/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="dual GIP/GLP-1 receptor agonists"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Drug class"/>
    </code>
    <valueCodeableConcept>
      <text value="non-steroidal mineralocorticoid receptor antagonist"/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description
                 value="non-steroidal mineralocorticoid receptor antagonists"/>
  </characteristic>
</Group>